Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global Implications
Aim The aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons. Methods An observational retrospective study was conducted using administrative databases from across Europe...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Formifarma, LDA.
2019-12-01
|
| Series: | Revista Portuguesa de Farmacoterapia |
| Online Access: | http://revista.farmacoterapia.pt/index.php/rpf/article/view/247 |
| _version_ | 1797733173904277504 |
|---|---|
| author | W Shrank B Godman M Andersen C Berg W Shrank I Bishop T Burkhardt K Garuoliene H Herholz R Joppi M Kalaba O Laius D McGinn V Samaluk C Sermet U Schwabe I Teixeira L Tilson FC Tulunay V Vlahović-Palčevski K Wendykowska B Wettermark C Zara LL Gustafsson |
| author_facet | W Shrank B Godman M Andersen C Berg W Shrank I Bishop T Burkhardt K Garuoliene H Herholz R Joppi M Kalaba O Laius D McGinn V Samaluk C Sermet U Schwabe I Teixeira L Tilson FC Tulunay V Vlahović-Palčevski K Wendykowska B Wettermark C Zara LL Gustafsson |
| author_sort | W Shrank |
| collection | DOAJ |
| description |
Aim
The aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons.
Methods
An observational retrospective study was conducted using administrative databases from across Europe, documenting changes in reimbursed utilization and expenditure of different proton pump inhibitors (PPIs) and statins between 2001 and 2007, alongside different reforms to enhance prescribing efficiency. Utilization was converted to defined daily doses (DDDs) and expenditures were converted to euros. Demand-side measures were collated under the ‘4 Es’-education, engineering, economics and enforcement-to enable comparisons on the nature and intensity of reforms between countries.
Results
There were considerable differences in the utilization of generics and patent-protected PPIs and statins among Western European countries. Decreased utilization of omeprazole and simvastatin, alongside increased utilization of esomeprazole, atorvastatin and rosuvastatin, was seen in countries with limited demand-side measures to counteract commercial pressures. Prescribing restrictions, or a combination of education, prescribing targets and financial incentives, had the greatest influence on enhancing the utilization of omeprazole and simvastatin. For example, there was a threefold reduction in the utilization of atorvastatin in Austria following prescribing restrictions. Multiple demand-side interventions generally had a greater influence than single interventions, with the impact appearing additive. Multiple interventions coupled with initiatives to lower prices of generics considerably enhanced prescribing efficiency.
Conclusion
This cross-national study has demonstrated considerable variation in the utilization and expenditure of PPIs and statins across Europe, providing opportunities to further improve prescribing efficiency. The ‘4 Es’ do provide an understandable methodology to document and compare the influence of different demand-side measures, with the influence varying by their extent and intensity. Further reforms are essential given current financial pressures. Consequently, further research will concentrate on the potential to develop a scoring system to help predict the possible impact of different demand-side measures on future utilization patterns.
Published in: Expert Rev Pharmacoecon Outcomes Res. 2010;10:707-22.
|
| first_indexed | 2024-03-12T12:25:23Z |
| format | Article |
| id | doaj.art-04b7f2a9b6594c78b2ca5ad470ffd61a |
| institution | Directory Open Access Journal |
| issn | 1647-354X 2183-7341 |
| language | English |
| last_indexed | 2024-03-12T12:25:23Z |
| publishDate | 2019-12-01 |
| publisher | Formifarma, LDA. |
| record_format | Article |
| series | Revista Portuguesa de Farmacoterapia |
| spelling | doaj.art-04b7f2a9b6594c78b2ca5ad470ffd61a2023-08-29T22:49:25ZengFormifarma, LDA.Revista Portuguesa de Farmacoterapia1647-354X2183-73412019-12-0111Sup 1Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global ImplicationsW ShrankB GodmanM AndersenC BergW ShrankI BishopT BurkhardtK GaruolieneH HerholzR JoppiM KalabaO LaiusD McGinnV SamalukC SermetU SchwabeI TeixeiraL TilsonFC TulunayV Vlahović-PalčevskiK WendykowskaB WettermarkC ZaraLL Gustafsson Aim The aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons. Methods An observational retrospective study was conducted using administrative databases from across Europe, documenting changes in reimbursed utilization and expenditure of different proton pump inhibitors (PPIs) and statins between 2001 and 2007, alongside different reforms to enhance prescribing efficiency. Utilization was converted to defined daily doses (DDDs) and expenditures were converted to euros. Demand-side measures were collated under the ‘4 Es’-education, engineering, economics and enforcement-to enable comparisons on the nature and intensity of reforms between countries. Results There were considerable differences in the utilization of generics and patent-protected PPIs and statins among Western European countries. Decreased utilization of omeprazole and simvastatin, alongside increased utilization of esomeprazole, atorvastatin and rosuvastatin, was seen in countries with limited demand-side measures to counteract commercial pressures. Prescribing restrictions, or a combination of education, prescribing targets and financial incentives, had the greatest influence on enhancing the utilization of omeprazole and simvastatin. For example, there was a threefold reduction in the utilization of atorvastatin in Austria following prescribing restrictions. Multiple demand-side interventions generally had a greater influence than single interventions, with the impact appearing additive. Multiple interventions coupled with initiatives to lower prices of generics considerably enhanced prescribing efficiency. Conclusion This cross-national study has demonstrated considerable variation in the utilization and expenditure of PPIs and statins across Europe, providing opportunities to further improve prescribing efficiency. The ‘4 Es’ do provide an understandable methodology to document and compare the influence of different demand-side measures, with the influence varying by their extent and intensity. Further reforms are essential given current financial pressures. Consequently, further research will concentrate on the potential to develop a scoring system to help predict the possible impact of different demand-side measures on future utilization patterns. Published in: Expert Rev Pharmacoecon Outcomes Res. 2010;10:707-22. http://revista.farmacoterapia.pt/index.php/rpf/article/view/247 |
| spellingShingle | W Shrank B Godman M Andersen C Berg W Shrank I Bishop T Burkhardt K Garuoliene H Herholz R Joppi M Kalaba O Laius D McGinn V Samaluk C Sermet U Schwabe I Teixeira L Tilson FC Tulunay V Vlahović-Palčevski K Wendykowska B Wettermark C Zara LL Gustafsson Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global Implications Revista Portuguesa de Farmacoterapia |
| title | Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global Implications |
| title_full | Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global Implications |
| title_fullStr | Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global Implications |
| title_full_unstemmed | Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global Implications |
| title_short | Comparing Policies to Enhance Prescribing Efficiency in Europe Through Increasing Generic Utilization: Changes Seen and Global Implications |
| title_sort | comparing policies to enhance prescribing efficiency in europe through increasing generic utilization changes seen and global implications |
| url | http://revista.farmacoterapia.pt/index.php/rpf/article/view/247 |
| work_keys_str_mv | AT wshrank comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT bgodman comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT mandersen comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT cberg comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT wshrank comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT ibishop comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT tburkhardt comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT kgaruoliene comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT hherholz comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT rjoppi comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT mkalaba comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT olaius comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT dmcginn comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT vsamaluk comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT csermet comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT uschwabe comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT iteixeira comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT ltilson comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT fctulunay comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT vvlahovicpalcevski comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT kwendykowska comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT bwettermark comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT czara comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications AT llgustafsson comparingpoliciestoenhanceprescribingefficiencyineuropethroughincreasinggenericutilizationchangesseenandglobalimplications |